Sitaxentan sodium

Sitaxentan sodium Basic information
Product Name:Sitaxentan sodium
Synonyms:Sodium (4-chloro-3-methyl-1,2-oxazol-5-yl)-[2-[2-(6-methyl-1,3-benzodioxol-5-yl)acetyl]thiophen-3-yl]sulfonylazanide;SITAXSENTAN SODIUM;TBC-11249;Thelin;sitaxentan sodiuM;N-(4-Chloro-3-Methylisoxazol-5-yl)-2-[2-(6-Methyl-1,3-Benzodioxol-5-yl)acetyl]thiophene-3-sulfonaMide;N-(4-Chloro-3-Methyl-5-isoxazolyl)-2-[2-(6-Methyl-1,3-benzodioxol-5-yl)acetyl]-3-thiophenesulfonaMide;TBC11251 sodiuM salt
CAS:210421-74-2
MF:C18H14ClN2NaO6S2
MW:476.89
EINECS:
Product Categories:Inhibitors;Sitaxsentan Sodium;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds
Mol File:210421-74-2.mol
Sitaxentan sodium Structure
Sitaxentan sodium Chemical Properties
storage temp. room temp
solubility H2O: soluble10mg/mL (clear solution)
form powder
color white to beige
Safety Information
WGK Germany 3
RTECS XN0296600
MSDS Information
Sitaxentan sodium Usage And Synthesis
DescriptionIn November Encysive Pharmaceuticals launched Thelin® (sitaxsentan sodium) in the U.K. for the treatment of pulmonary arterial hypertension (PAH), following European Commission approval in August 2006. Sitaxsentan is the first selective endothelin A (ETA) receptor antagonist, and the first once-daily oral treatment available for patients with PAH. It is 6,500-fold selective in the targeting of ETA versus ETB receptors. Sitaxsentan is indicated for improving exercise capacity in PAH patients classified as World Health Organization (WHO) functional class III. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease. In the U.S., Encysive has submitted a complete response to an approvable letter received from the FDA in July.
DescriptionSitaxentan is a potent nonpeptide endothelin A (ETA) receptor antagonist (IC50 = 1.4 nM). It is selective for ETA over ETB receptors (IC50 = 9,800 nM). Sitaxentan inhibits phosphoinositol hydrolysis induced by endothelin-1 in COS-7 cells (pA2 = 8). In vivo, sitaxentan reduces blood pressure in a rat model of acute hypoxia-induced pulmonary hypertension (ED50 = 0.5 mg/kg). It reduces femoral artery neointimal lesion size in a mouse model of intraluminal injury. Sitaxentan (15 mg/kg) decreases bronchoalveolar lavage fluid (BALF) pleocytosis, as well as pulmonary collagen deposition and fibrosis, and improves lung mechanics in a mouse model of bleomycin-induced lung injury. Formulations containing sitaxentan have been used in the treatment of hypertension.
UsesSelective endothelin A (ETA) receptor antagonist. Antihypertensive. Used in treatment of chronic heart failure.
General DescriptionSitaxentan sodium, belongs to thesulfonamide class of endothelin receptor antagonists.Although it has 6,000-fold selectivity for the ETA receptor,clinical trials have not demonstrated a greater efficacyover bosentan. However, it has much lower liver toxicitythan bosentan. The manufacturer is attempting to meetefficacy outcomes set by the FDA, which must be met beforeapproval of sitaxsentan as a therapeutic agent will begranted.
Biochem/physiol ActionsSitaxentan (Sitaxsentan) is a potent and selective endothelin ET(A) receptor antagonist once used in the treatment of pulmonary arterial hypertension (PAH), but removed from the market because of hepatotoxicity. It is over 6000-fold selective for the the ETA receptor subtype with an IC50 of 1 nM for ETA versus an IC50 of 9800 nM for ETB.
SynthesisThe synthesis of sitaxentan is depicted in Scheme 12. 5-amino-3- methylisoxazole 85 was treated with NCS in DCM at 0??C to give chloroisoxazole 86 in 87% yield. The amine was then coupled with the commercially available 2-(methoxycarbonyl)- 3-thiophenesulfonyl chloride (87) using sodium hydride in THF at 0??C. The resulting ester was directly hydrolyzed in 1N NaOH to furnish acid 88 in 45% yield. The acid 88 was then coupled with N,O-dimethylhydroxylamine to give Weinreb amide 89. The amide 89 was then treated with benzylic Grignard reagent followed by acidic workup to give the sitaxentan XII in 50% yield in two steps. The Grignard reagent 90 was prepared through the following sequence. The 5-methylbenzodioxole 91 was treated with aqueous formaldehyde and concentrated HCl in ethyl ether to give the desired benzyl chloride 93 and condensation product 92. The mixture of 92 and 93 was used to form the Grignard reagent without separation.

Synthesis_210421-74-2

Sitaxentan sodium Preparation Products And Raw materials
Sitravatinib Sulbactam sodium Sivelestat sodium Skepinone-L Sitaxentan sodium N- (4- chloro- 3- methyl- oxazol- 5- yl)- 2- [2- (6- methylbenzo[1,3]dioxol- 5- yl)acetyl]- thiophene- 3- sulfonamide 5-AMINO-4-CHLORO-3-METHYLISOXAZOLE

Email:[email protected] [email protected]
Copyright © 2024 Mywellwork.com All rights reserved.